Clinical trials
Terminated Melanoma trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
400 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 3 |
| 2003 | 4 |
| 2004 | 9 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 11 |
| 2008 | 18 |
| 2009 | 17 |
| 2010 | 19 |
| 2011 | 23 |
| 2012 | 18 |
| 2013 | 28 |
| 2014 | 21 |
| 2015 | 21 |
| 2016 | 19 |
| 2017 | 19 |
| 2018 | 29 |
| 2019 | 24 |
| 2020 | 19 |
| 2021 | 28 |
| 2022 | 17 |
| 2023 | 13 |
| 2024 | 10 |
| 2025 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 400 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 43 |
| M.D. Anderson Cancer Center | 19 |
| Pfizer | 16 |
| Mayo Clinic | 11 |
| Novartis Pharmaceuticals | 10 |
| Bristol-Myers Squibb | 6 |
| University of Southern California | 6 |
| Craig L Slingluff, Jr | 5 |
| National Institutes of Health Clinical Center (CC) | 5 |
| Seagen Inc. | 5 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Melanoma | 400 |
| Carcinoma, Non-Small-Cell Lung | 79 |
| Neoplasm Metastasis | 57 |
| Carcinoma, Renal Cell | 51 |
| Neoplasms | 47 |
| Colorectal Neoplasms | 43 |
| Squamous Cell Carcinoma of Head and Neck | 38 |
| Breast Neoplasms | 36 |
| Skin Neoplasms | 35 |
| Ovarian Neoplasms | 30 |
Trials
Showing 1 to 25 of 400. Each trial links to its page on Pharma Observatory.
300 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.